00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
18:10 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML); pancreatic cancer Cell culture and mouse studies suggest a small molecule modulator of the SF3B splicing complex could help treat cancers with mutations in spliceosome...
21:10 , Feb 20, 2018 |  BC Extra  |  Preclinical News

New compound kills tumor cells with spliceosome mutations

In a Nature Medicine study , researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy data for Phase I candidate H3B-8800, a potentially first-in-class mRNA splicing inhibitor for cancers harboring spliceosome mutations....
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting SF3B1 could help treat secondary AML in elderly patients. Leukemic stem cells from elderly patients with secondary AML exhibited a different...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Serine/arginine-rich splicing factor 2 (SRSF2); splicing factor 3B subunit 1 (SF3B1)

Cancer INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting SF3B1 could help treat SRSF2-mutant AML. In a mouse model of SRSF2-mutant AML, an SF3B1 inhibitor tool compound that blocks missplicing of mutant SRSF2 increased...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Imetelstat: Additional Phase II data

Additional data from an investigator-sponsored, open-label, U.S. Phase II trial in 33 patients with intermediate-2 or high-risk primary or secondary MF showed that IV 9.4 mg/kg imetelstat led to an ORR of 21%, including 4...
01:08 , Sep 4, 2015 |  BC Extra  |  Clinical News

Geron rises on published Phase II imetelstat data

Geron Corp. (NASDAQ:GERN) climbed $0.40 (13%) to $3.45 on Thursday after data from two Phase II trials of imetelstat ( GRN163L ) to treat essential thrombocythemia (ET) and myelofibrosis (MF) were published in The New...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Multiplicom sales and marketing update

Multiplicom launched the CLL MASTR Plus Kit worldwide for research use only to improve diagnosis of patients with chronic lymphocytic leukemia (CLL). The mutation kit identifies mutations tumor protein p53 (TP53) ; baculoviral IAP repeat-containing...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

University of Tokyo, Qiagen deal

The university granted Qiagen exclusive, worldwide rights to splicing factor 3B subunit 1 (SF3B1) . Qiagen said SF3B1 mutation status is a biomarker for prognosis in patients with myelodysplastic syndromes (MDS). The company plans to...